Drug intelligence / Profile preview

GTC-3295

Development stage: Preclinical
Lead developer: Gismo Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

GTC-3295 is an orally available, brain-penetrant small molecule therapeutic candidate developed by Gismo Therapeutics using its proprietary Glycosaminoglycan-Interacting Small Molecule (GISMO) platform. It is designed to act as a dual inhibitor of amyloid-beta and tau interactions with heparan sulfate glycosaminoglycans (HS-GAGs). By blocking these interactions, GTC-3295 aims to prevent the internalization, aggregation, and propagation of toxic amyloid-beta and tau proteopathic seeds in the brain. The drug is currently undergoing IND-enabling preclinical studies for the treatment of Alzheimer's disease, supported by SBIR grants from the National Institute on Aging.

Targets

Aβ (Amyloid-beta peptides and aggregates)MAPT (Microtubule-associated protein tau)HS (Heparan sulfate)

Beyond the preview

Go deeper on GTC-3295.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GTC-3295.

Explore the full profile